Skip to content

Orchid Can't Nix Roche Boniva Patent

By Samuel Howard, Law360
Loeb & Loeb LLP's Mark Waddell and Paula Colbath are noted as counsel for Hoffmann-La Roche Inc. in the pharmaceutical company's infringement actions against Orchid Chemicals & Pharmaceuticals Ltd. over Orchid's proposed generic version of the branded osteoporosis drug Boniva®. A federal judge rejected Orchid's bid to toss one of the five Boniva® patents asserted by Roche to prevent Orchid from marketing the generic drug.